A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Clinical trial NCT05606380 · UNKNOWN
Trial details
- NCT number
- NCT05606380
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-02
- Primary completion
- 2024-08-01
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.